Relationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
received:
22
03
2024
accepted:
08
05
2024
medline:
31
7
2024
pubmed:
31
7
2024
entrez:
31
7
2024
Statut:
epublish
Résumé
Alcohol-associated hepatitis (AH) is associated with significant mortality. Model for End-Stage Liver Disease (MELD) score is used to predict short-term mortality and aid in treatment decisions. MELD is frequently updated in the course of AH. However, once the most updated MELD is known, it is uncertain if previous ones still have prognostic value, which might be relevant for transplant allocation and trial design. We aimed to investigate the predictive performance of updated MELDs in a prospectively collected cohort of patients with AH by the InTeam consortium. Three hundred seven patients (with 859 MELD values within 60 d of admission) fulfilled the inclusion criteria. The main endpoint was time to death or transplant up to 90 days. We used a joint model approach to assess the predictive value of updated MELDs. Updated MELD measurements had a strong prognostic value for death/transplant (HR: 1.20, 95% CI: 1.14-1.27) (p < 0.0001). Previous MELD values did not add predictive value to the most current MELD. We also showed that MELD at day 28 (MELD28) had a significant predictive value for subsequent mortality/transplant in a landmark analysis (HR: 1.18, 95% CI: 1.12-1.23). We show that the use of an ordinal scale including death, transplant, and MELD28 as a trial outcome could substantially reduce the sample size required to demonstrate short-term benefit of an intervention. We show that updated MELDs during the trajectory of AH predict subsequent mortality or the need for transplant. MELD28 inclusion in an ordinal outcome (together with death or transplant) could increase the efficiency of randomized controlled trials.
Sections du résumé
BACKGROUND
BACKGROUND
Alcohol-associated hepatitis (AH) is associated with significant mortality. Model for End-Stage Liver Disease (MELD) score is used to predict short-term mortality and aid in treatment decisions. MELD is frequently updated in the course of AH. However, once the most updated MELD is known, it is uncertain if previous ones still have prognostic value, which might be relevant for transplant allocation and trial design. We aimed to investigate the predictive performance of updated MELDs in a prospectively collected cohort of patients with AH by the InTeam consortium.
METHODS
METHODS
Three hundred seven patients (with 859 MELD values within 60 d of admission) fulfilled the inclusion criteria. The main endpoint was time to death or transplant up to 90 days. We used a joint model approach to assess the predictive value of updated MELDs.
RESULTS
RESULTS
Updated MELD measurements had a strong prognostic value for death/transplant (HR: 1.20, 95% CI: 1.14-1.27) (p < 0.0001). Previous MELD values did not add predictive value to the most current MELD. We also showed that MELD at day 28 (MELD28) had a significant predictive value for subsequent mortality/transplant in a landmark analysis (HR: 1.18, 95% CI: 1.12-1.23). We show that the use of an ordinal scale including death, transplant, and MELD28 as a trial outcome could substantially reduce the sample size required to demonstrate short-term benefit of an intervention.
CONCLUSION
CONCLUSIONS
We show that updated MELDs during the trajectory of AH predict subsequent mortality or the need for transplant. MELD28 inclusion in an ordinal outcome (together with death or transplant) could increase the efficiency of randomized controlled trials.
Identifiants
pubmed: 39082963
doi: 10.1097/HC9.0000000000000495
pii: 02009842-202408010-00014
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.
Références
Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KVN, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005;41:353–358.
Arab JP, Díaz LA, Baeza N, Idalsoaga F, Fuentes-López E, Arnold J, et al. Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. J Hepatol. 2021;75:1026–1033.
Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol. 2005;42:700–706.
Forrest EH, Evans CD, Stewart S, Phillips M, Oo YH, McAvoy NC, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut. 2005;54:1174–1179.
Maddrey WC, Boitnott JK, Bedine MS, Weber FL, Mezey E, White RI. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978;75:193–199.
Dominguez M, Rincón D, Abraldes JG, Miquel R, Colmenero J, Bellot P, et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol. 2008;103:2747.
Morales-Arráez D, Ventura Cots M, Altamirano J, Abraldes JG, Cruz-Lemini M, Thursz MR, et al. The MELD score is superior to Maddrey’s discriminant function score to predict short-term mortality in alcohol-associated hepatitis: A global study. Am J Gastroenterol. 2022;117:301–310.
Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PCJ. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864–871.
Parker R, Cabezas J, Altamirano J, Arab JP, Ventura-Cots M, Sinha A, et al. Trajectory of serum bilirubin predicts spontaneous recovery in a real-world cohort of patients with alcoholic hepatitis. Clin Gastroenterol Hepatol. 2022;20:e289–e297.
Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, et al. The Lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007;45:1348–54.
Louvet A, Labreuche J, Artru F, Boursier J, Kim DJ, O’Grady J, et al. Combining data from liver disease scoring systems better predicts outcomes of patients with alcoholic hepatitis. Gastroenterology. 2015;149:398–406.e8.
Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol-associated liver diseases: 2019 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2020;71:306–333.
Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015;372:1619–1628.
Louvet A, Labreuche J, Dao T, Thévenot T, Oberti F, Bureau C, et al. Effect of prophylactic antibiotics on mortality in severe alcohol-related hepatitis: A randomized clinical trial. JAMA. 2023;329:1558–1566.
Nguyen-Khac E, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011;365:1781–1789.
Crabb DW, Bataller R, Chalasani NP, Kamath PS, Lucey M, Mathurin P, et al. Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: Recommendation from the NIAAA Alcoholic Hepatitis Consortia. Gastroenterology. 2016;150:785–790.
Musto JA, Eickhoff J, Ventura‐Cots M, Abraldes JG, Bosques‐Padilla F, Verna EC, et al. The level of alcohol consumption in the prior year does not impact clinical outcomes in patients with alcohol-associated hepatitis. Liver Transpl. 2021;27:1382–1391.
Rizopoulos D, Papageorgiou G, Afonso PM JMbayes2: Extended joint models for longitudinal and time-to-event data. March 13, 2023. Accessed May 2, 2023. https://cran.r-project.org/web/packages/JMbayes2/index.html
Therneau TM, Lumley T (original S>R port and R maintainer until 2009), Elizabeth A, Cynthia C. survival: Survival Analysis. March 12, 2023. Accessed May 2, 2023. https://cran.r-project.org/web/packages/survival/index.html
Harrell Jr FE. rms: Regression Modeling Strategies. April 9, 2023. Accessed May 2, 2023. https://cran.r-project.org/web/packages/rms/index.html
Harrell Jr FE, Dupont C (contributed several functions and maintains latex functions). Hmisc: Harrell Miscellaneous. May 8, 2023. Accessed July 27, 2023. https://cran.r-project.org/web/packages/Hmisc/index.html
Dynamic predictions. Accessed July 26, 2023. https://drizopoulos.github.io/JMbayes2/articles/Dynamic_Predictions.html
Univariate and multivariate joint models. Accessed July 26, 2023. https://drizopoulos.github.io/JMbayes2/articles/JMbayes2.html
Carithers RL Jr, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med. 1989;110:685–690.
Louvet A, Thursz MR, Kim DJ, Labreuche J, Atkinson SR, Sidhu SS, et al. Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo—A meta-analysis of individual data from controlled trials. Gastroenterology. 2018;155:458–468.e8.
Higuera-de la Tijera F, Servín-Caamaño AI, Serralde-Zúñiga AE, Cruz-Herrera J, Pérez-Torres E, Abdo-Francis JM, et al. Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis. World J Gastroenterol. 2015;21:4975–4985.
Hassanein T, McClain CJ, Vatsalya V, Stein LL, Flamm SL, Martin P, et al. Safety, pharmacokinetics, and efficacy signals of larsucosterol (DUR-928) in alcohol-associated hepatitis. Am J Gastroenterol. 2024;119:107–115.
Mathurin P, Dufour J-F, Bzowej NH, Shiffman ML, Arterburn S, Nguyen T, et al. Selonsertib in combination with prednisolone for the treatment of severe alcoholic hepatitis: a phase 2 randomized controlled trial. Hepatology. 2018;68:8A–9A.
Conatus Pharmaceuticals Inc. A placebo-controlled, multicenter, double-blind, randomized trial of IDN-6556 in patients with severe alcoholic hepatitis and contraindications to corticosteroid therapy. clinicaltrials.gov. 2016. Accessed July 26, 2023. https://clinicaltrials.gov/study/NCT01912404
Virginia Commonwealth University. A multicenter randomized, double-blind, placebo-controlled, dosing, safety and efficacy study of IMM 124-E (hyperimmune bovine colostrum) for patients with severe alcoholic hepatitis. clinicaltrials.gov. 2020. Accessed July 26, 2023. https://clinicaltrials.gov/study/NCT01968382
Mitchell M. Novel therapies in moderately severe acute alcoholic hepatitis. clinicaltrials.gov. 2022. Accessed July 26, 2023. https://clinicaltrials.gov/study/NCT01922895
Harrell F. Statistical thinking—Violation of proportional odds is not fatal. September 20, 2020. Accessed July 27, 2023. https://www.fharrell.com/post/po/
Anderson CS, Robinson T, Lindley RI, Arima H, Lavados PM, Lee TH, et al. Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke. N Engl J Med. 2016;374:2313–2323.
Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Mentré F, Burdet C, et al. Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19. Lancet Infect Dis. 2022;22:764–765.
Hoeper MM, Badesch DB, Ardeschir Ghofrani H, Gibbs SR, Gomberg-Maitland M, McLaughlin VV, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388:1478–1490.
Louvet A, Labreuche J, Artru F, Bouthors A, Rolland B, Saffers P, et al. Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: A prospective study. Hepatology. 2017;66:1464.
Altamirano J, López‐Pelayo H, Michelena J, Jones PD, Ortega L, Ginès P, et al. Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: Prediction and impact on long‐term survival. Hepatology. 2017;66:1842.
Cotter TG, Sandikçi B, Paul S, Gampa A, Wang J, Te H, et al. Liver transplantation for alcoholic hepatitis in the United States: Excellent outcomes with profound temporal and geographic variation in frequency. Am J Transplant. 2021;21:1039–1055.
Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018–1026.
Kim WR, Mannalithara A, Heimbach JK, Kamath PS, Asrani SK, Biggins SW, et al. MELD 3.0: The Model for End-Stage Liver Disease updated for the modern era. Gastroenterology. 2021;161:1887–1895.e4.